▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #118 by analyst upside · 2026-09-27
RANI
Rani Therapeutics Holdings, Inc.
Healthcare · Market Cap $107M · P/E 0x
ANALYST PRICE TARGET
+848.4%
implied upside to consensus target
Current Price $0.76
Consensus Target $7.2
Bull Target $11.0
Bear Target $5.0
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
4
Hold
0
Sell
0
52-Week Low $0.45
52-Week High $3.87
YTD Return -44.2%
FUNDAMENTALS
Market Cap $107M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.13
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $5M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.45
52-Week High $3.87
Current Price $0.76
Bear Target $5.0
Bull Target $11.0
● Now $0.76 ● Target $7.2
TRADING DATA
Avg Volume 776K
YTD Return -44.2%
Analyst Count 5
Consensus Buy
Upside to Target +848.4%
Last Updated 2026-09-27

ANALYST SUMMARY

Rani Therapeutics Holdings, Inc. (RANI) is currently trading at $0.76 with a Wall Street consensus price target of $7.2, implying potential upside of 848.4% over the next 12 months. 5 analysts currently cover RANI, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $11.0, while the most cautious has a target of $5.0.

RANI operates in the Healthcare sector with a market capitalisation of $107M. The stock is down 44.2% year-to-date and is currently trading near the lower end of its 52-week range of $0.45 – $3.87.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for RANI, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-08-21 31% win rate (48 calls)
Chardan Capital ● Initiated
Buy 2026-08-18 33% win rate (6 calls)
Canaccord Genuity - Reiterated
Buy → Buy 2026-05-20 Building track record
Canaccord Genuity - Reiterated
Buy → Buy 2026-04-01 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-03-27 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-01-09 31% win rate (48 calls)
Maxim Group - Reiterated
Buy → Buy 2025-10-20 28% win rate (40 calls)
Oppenheimer - Reiterated
Outperform → Outperform 2025-05-16 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
41
out of 100
Coverage depth
14/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →